导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.23% | 1887/4773 |
| 近一周 | -1.97% | 3205/5465 |
| 近一月 | -1.07% | 1016/5421 |
| 近一季 | -3.91% | 1710/5231 |
| 近半年 | -7.61% | 3383/4920 |
| 近一年 | 6.48% | 1589/4394 |
| 近两年 | 32.80% | 2176/2954 |
| 近三年 | 22.52% | 1398/2253 |
| 成立以来 | 85.01% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.60% 694/4961 |
2.01% 2973/5312 |
- - |
- - |
| 2025 | 7.45% 2926/4813 |
-4.60% 3207/3635 |
1.10% 2460/4076 |
7.54% 3445/4524 |
3.59% 655/4813 |
| 2024 | 19.17% 548/3463 |
9.60% 125/2808 |
1.99% 418/3014 |
7.82% 2801/3129 |
-1.12% 1595/3463 |
| 2023 | 7.66% 137/2656 |
16.84% 190/2280 |
1.33% 220/2385 |
-3.47% 939/2515 |
-5.80% 1505/2655 |
| 2022 | -12.32% 276/2207 |
-10.95% 461/1919 |
2.81% 1256/2016 |
-9.69% 297/2113 |
6.05% 395/2208 |
| 2021 | 28.12% 85/1822 |
3.17% 195/1255 |
3.94% 943/1330 |
18.26% 63/1466 |
1.03% 1020/1822 |
| 2020 | 11.93% 816/1250 |
-8.01% 585/1028 |
-0.12% 1012/1067 |
9.94% 603/1164 |
10.80% 580/1184 |
| 2019 | - - |
- - |
- - |
- - |
-1.25% 898/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实中证央企创新驱动ETF VS. 长安沪深300非周期A(740101) |